Tobramycin Ophthalmic Solution
PrescriptionТорговые наименования: Tobramycin Ophthalmic Solution
About This Medication
DESCRIPTION Tobramycin ophthalmic solution USP, 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections. Each mL of Tobramycin Ophthalmic Solution USP contains: Active : tobramycin 0.3% (3 mg). Preservative : benzalkonium chloride 0.01% (0.1 mg). Inactives : boric acid, sodium sulfate decahydrate, sodium chloride, tyloxapol, sodium hydroxide and/or sulfuric acid (to adjust pH) and water for injection. Tobramycin ophthalmic solution USP, 0.3% has a pH range between 7.0 and 8.0 and an osmolality of 260 to 320 mOsm/kg. Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens. The chemical structure of tobramycin is: Molecular Weight = 467.52 Molecular Formula: C 18 H 37 N 5 O 9 Chemical name: 0-{3-amino-3-deoxy-α-D-gluco-pyranosyl-(1→4)}-0-{2,6-diamino-2,3,6-trideoxy-α-D-ribohexo -pyranosyl-(1→6)}-2-deoxystreptamine. tobra-struc
Действующие Вещества
| Компонент | Дозировка |
|---|---|
| Tobramycin | - |
Показания и Применение
Дозировка и Способ Применения
Side Effects Overview
Предупреждения и Меры Предосторожности
WARNINGS FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to Tobramycin ophthalmic solution, 0.3% occurs, discontinue use.
Противопоказания
CONTRAINDICATIONS Tobramycin ophthalmic solution, 0.3% is contraindicated in patients with known hypersensitivity to any of its components.
Frequently Asked Questions
INDICATIONS AND USAGE Tobramycin ophthalmic solution, 0.3 % is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution. Clinical studies have shown tobramycin to be safe and effective for use in children.
DOSAGE AND ADMINISTRATION In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.
WARNINGS FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to Tobramycin ophthalmic solution, 0.3% occurs, discontinue use.
CONTRAINDICATIONS Tobramycin ophthalmic solution, 0.3% is contraindicated in patients with known hypersensitivity to any of its components.
Tobramycin Ophthalmic Solution is a prescription medication. You will need a valid prescription from a licensed healthcare provider.
Similar Drops Products
Browse all Drops products →References & Data Sources
- • DailyMed — Tobramycin Ophthalmic Solution drug label (National Library of Medicine)
- • openFDA — Tobramycin Ophthalmic Solution label data (U.S. Food & Drug Administration)
- • RxNorm — RXCUI 313415 (NLM Normalized Drug Names)
- • NDC Directory — Tobramycin Ophthalmic Solution (FDA National Drug Code)
Медицинский Отказ от Ответственности
Информация на данной странице предназначена исключительно в образовательных целях и не должна использоваться в качестве замены профессиональной медицинской консультации, диагностики или лечения.
Всегда обращайтесь за советом к своему врачу или иному квалифицированному медицинскому работнику по любым вопросам, связанным с состоянием здоровья или лекарственными препаратами.
Источники данных: DailyMed (NLM), openFDA, MFDS